Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 20, Issue 2, Pages 163-172
Publisher
Informa UK Limited
Online
2018-11-25
DOI
10.1080/14656566.2018.1548611
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer
- (2018) Athanasios E. Dellis et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Discovery and development of ODM-204: A Novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1
- (2018) Riikka Oksala et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
- (2018) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of non-metastatic castrate-resistant prostate cancer: a systematic review
- (2018) Yohann Loriot et al. CANCER TREATMENT REVIEWS
- Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer
- (2018) Karim Fizazi et al. Clinical Genitourinary Cancer
- Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer
- (2017) Howard I. Scher et al. EUROPEAN UROLOGY
- Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
- (2017) Tomasz M. Beer et al. EUROPEAN UROLOGY
- Darolutamide (ODM-201) for the treatment of prostate cancer
- (2017) Neal D. Shore EXPERT OPINION ON PHARMACOTHERAPY
- A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer
- (2017) Evan Y. Yu et al. INVESTIGATIONAL NEW DRUGS
- A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers
- (2016) K. N. Chi et al. ANNALS OF ONCOLOGY
- Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence
- (2016) Isabel Coutinho et al. ENDOCRINE-RELATED CANCER
- Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer
- (2016) Athanasios Dellis et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial
- (2016) David F. Penson et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study
- (2016) Neal D Shore et al. LANCET ONCOLOGY
- Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer
- (2016) E. S. Antonarakis et al. ONCOLOGIST
- Utility of novel androgen receptor therapies in the real world: A nuanced approach
- (2016) Mallika Dhawan et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Novel and next-generation androgen receptor–directed therapies for prostate cancer: Beyond abiraterone and enzalutamide
- (2016) Richard M. Bambury et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) C. Parker et al. ANNALS OF ONCOLOGY
- Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate
- (2015) G. Attard et al. CLINICAL CANCER RESEARCH
- Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
- (2015) A. A. Azad et al. CLINICAL CANCER RESEARCH
- Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance
- (2015) DJ Crona et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Observational studies and the natural history of screen-detected prostate cancer
- (2015) Peter C. Albertsen CURRENT OPINION IN UROLOGY
- ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer
- (2015) Karim Fizazi et al. Expert Review of Anticancer Therapy
- AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies
- (2015) A. Omlin et al. INVESTIGATIONAL NEW DRUGS
- Discovery and Development of Galeterone (TOK-001 or VN/124-1) for the Treatment of All Stages of Prostate Cancer
- (2015) Vincent C. O. Njar et al. JOURNAL OF MEDICINAL CHEMISTRY
- Castration-Resistant Prostate Cancer: AUA Guideline Amendment
- (2015) Michael S. Cookson et al. JOURNAL OF UROLOGY
- Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations
- (2015) Daan Joost De Maeseneer et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Androgen receptor aberrations in the era of abiraterone and enzalutamide
- (2015) Florian Jentzmik et al. WORLD JOURNAL OF UROLOGY
- Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer
- (2015) Aaron Balog et al. ACS Medicinal Chemistry Letters
- Abstract 614: Proxalutamide (GT0918), a potent androgen receptor pathway inhibitor
- (2015) Youzhi Tong et al. CANCER RESEARCH
- Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
- (2015) Anu-Maarit Moilanen et al. Scientific Reports
- Galeterone Prevents Androgen Receptor Binding to Chromatin and Enhances Degradation of Mutant Androgen Receptor
- (2014) Z. Yu et al. CLINICAL CANCER RESEARCH
- Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial
- (2014) Karim Fizazi et al. LANCET ONCOLOGY
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer
- (2013) D Bianchini et al. BRITISH JOURNAL OF CANCER
- Androgen Receptor Antagonists in Castration-Resistant Prostate Cancer
- (2013) Dana Rathkopf et al. CANCER JOURNAL
- Castration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment
- (2013) Srikala S. Sridhar et al. EUROPEAN UROLOGY
- Serum Androgens As Prognostic Biomarkers in Castration-Resistant Prostate Cancer: Results From an Analysis of a Randomized Phase III Trial
- (2013) Charles J. Ryan et al. JOURNAL OF CLINICAL ONCOLOGY
- Systematic Structure Modifications of Multitarget Prostate Cancer Drug Candidate Galeterone To Produce Novel Androgen Receptor Down-Regulating Agents as an Approach to Treatment of Advanced Prostate Cancer
- (2013) Puranik Purushottamachar et al. JOURNAL OF MEDICINAL CHEMISTRY
- AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo
- (2013) S. A. Loddick et al. MOLECULAR CANCER THERAPEUTICS
- Androgen receptors in hormone-dependent and castration-resistant prostate cancer
- (2013) Ayesha A. Shafi et al. PHARMACOLOGY & THERAPEUTICS
- A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
- (2013) J. D. Joseph et al. Cancer Discovery
- Overcoming mutation-based resistance to antiandrogens with rational drug design
- (2013) Minna D Balbas et al. eLife
- Abiraterone and Novel Antiandrogens: Overcoming Castration Resistance in Prostate Cancer
- (2012) R. Ferraldeschi et al. Annual Review of Medicine
- Progress in emerging therapies for advanced prostate cancer
- (2012) Stéphane Oudard CANCER TREATMENT REVIEWS
- Abiraterone acetatefor the treatment of prostate cancer
- (2012) Charles J Ryan et al. EXPERT OPINION ON PHARMACOTHERAPY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Alterations during Progression of Prostate Cancer to Androgen Independence
- (2011) P. Saraon et al. CLINICAL CHEMISTRY
- Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer
- (2011) Vincenzo Pagliarulo et al. EUROPEAN UROLOGY
- Reduced Expression of the Androgen Receptor by Third Generation of Antisense Shows Antitumor Activity in Models of Prostate Cancer
- (2011) Y. Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
- (2010) Raymond J. Andersen et al. CANCER CELL
- Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer
- (2010) D. Rathkopf et al. CLINICAL CANCER RESEARCH
- Molecular genetics of prostate cancer: new prospects for old challenges
- (2010) M. M. Shen et al. GENES & DEVELOPMENT
- Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
- (2010) P. A. Watson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values
- (2009) Vivek K. Wadhwa et al. BJU INTERNATIONAL
- Treatment-Dependent Androgen Receptor Mutations in Prostate Cancer Exploit Multiple Mechanisms to Evade Therapy
- (2009) M. P. Steinkamp et al. CANCER RESEARCH
- A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion-Resistant Growth
- (2009) Z. Guo et al. CANCER RESEARCH
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance
- (2008) S. M. Dehm et al. CANCER RESEARCH
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- (2008) R. B. Montgomery et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More